The genomic features associated with high-risk multiple myeloma.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. Impact of NRAS mutation on efficacy of triplet induction therapy in newly diagnosed multiple myeloma.Journal of clinical and experimental hematopathology : JCEH · 2025
   Article
2. Management of Multiple Myeloma: A Review for General Practitioners in Oncology.Current oncology (Toronto, Ont.) · 2023
   Review
3. Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
   Article
4. Bortezomib, epirubicin, and dexamethasone (PAD) results in superior free-progression survival compared to bortezomib, cyclophosphamide, and dexamethasone (VCD) treatment in non-transplantation newly diagnosed multiple myeloma patients aged between 50 to 65: a retrospective single-center analysis in non-transplant patients.Annals of translational medicine · 2022
   Article
5. Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications.Cells · 2021
   Review
6. [Multiple-Hit myeloma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2019
   Article

Corrections and comments

• Comment on
  A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis.2019

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as